This 15mg blend pairs tesamorelin (a modified GHRH analog) with ipamorelin (a selective GHS-R1a agonist) to support research examining concurrent activation of complementary growth hormone regulatory pathways. Published literature describes the distinct but convergent mechanisms through which GHRH analogs and ghrelin-mimetic peptides influence somatotroph function.
Tesamorelin’s trans-hexenoic acid modification and ipamorelin’s pentapeptide selectivity profile have each been independently characterized in peer-reviewed studies. The blended format enables researchers to investigate the combined signaling dynamics of these two well-documented compounds within a single experimental preparation, reducing protocol complexity.
Both peptide components are analytically verified within the blend, with chromatographic methods confirming the identity, ratio, and purity of each constituent. The lyophilized format maintains stability of both components during storage and shipping.
Intended for in-vitro and laboratory research only. Not for human or veterinary use.
